NEWS & COMMENTS

PROHOST    FILTER

                                                   Eye  On

      INFLATION?

       A fair conclusion about inflation has been finally reached, which tells us that there is no inflation in sight as the successive increases in interest rate have already slowed the economy. In summary, there is no more increase in interest rate until further notice about any changes in the economy. It seems that the market liked this conclusion and decided to make happy those who buy public companies’ stocks. You know what? Happiness brings happiness and probably prosperity as the mood yesterday was very optimistic, reflected on more spending. We saw it on the faces of people who filled the shopping centers, restaurants, movies and theatres. Wish those who have not lost hope in their well-selected stocks more happiness.  

IN THE

CRUCELL’s (CRXL) PER.C6® cell line is a breakthrough that is increasingly seeked by drug companies to develop vaccines and monoclonal antibody therapeutics. With its partner DSM Biologics, Crucell signed a second PER.C6® license agreement with MorphoSys AG. The agreement allows MorphoSys to use the cell line in the production of clinical grade material for the development of its therapeutic antibody program MOR103. MOR103 is a fully human HuCAL® antibody for inflammatory diseases, such as rheumatoid arthritis.

Further, MorphoSys has signed a Biopharmaceutical Manufacturing Agreement with DSM Biologics to produce the clinical grade material in its FDA-approved facilities in Groningen, the Netherlands. Further financial details on these agreements were not disclosed.

Read Prohost rating of Crucell in the Prohost E-letter and the N-letter (For subscribers only).  

READ MORE: Crucell and DSM Biologics Announce Second PER.C6 Licensing Agreement With MorphoSys

CYTOGEN (CYTO): The firm announced that SOLTAMOX™ (tamoxifen citrate, oral solution 10mg/5mL), the first liquid form of the hormonal breast cancer therapy tamoxifen, is now available in U.S. pharmacies nationwide. SOLTAMOX received U.S. Food and Drug Administration marketing approval in October 2005 and is indicated for the treatment of metastatic breast cancer and to reduce the incidence of breast cancer in women who are at high risk for the disease.  

Why Liquid?

Because of the difficulty in swallowing (dysphagia), which is commonly caused by cancer treatments, especially chemotherapy and radiation. Cancer patients with dysphagia experience problems swallowing pills due to mouth and throat sores, inflammation or dry mouth. To address this problem, many patients resort to cutting or crushing drugs administered in pill form, which can lead to risks including altered dosing efficacy or side effects associated with improper dosing. In addition, patients with dysphagia may be less likely to comply with prescribed regimens because swallowing is difficult or painful.

READ MORE: Cytogen Launches SOLTAMOX(TM), First Oral Liquid Formulation of Hormonal Therapy for Breast Cancer Patients

Is there other news?

Prohost is independent publication providing information on biotech companies. Prohost does not accept compensation from companies that are featured or profiled. It is strongly recommended that any purchase or sale decisions to any of the featured companies be discussed with a financial advisor or broker prior to completing any such purchase or sale decision. All statements or expressions are the opinion of Prohost and are not meant to be a solicitation or recommendation to buy, sell, or hold securities. Investing in embryonic companies, micro-cap and growth securities is highly speculative and carries a high degree of risk. It is possible that an investor can lose all of his/her investment in this type of companies that are profiled. The information that Prohost relies on is either through the profiled company, news services, research reports, interviews, or other outside sources that Prohost believes are reliable. Prohost makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure of the profiled companies and accepts no responsibilities for inaccuracies or misleading content in any material supplied by those clients. There can be no assurance that future events relating to the profiled company will occur as anticipated. The information contained herein is provided as an information service only. Past performance of featured companies does not guarantee the future success of any currently featured or profiled company. We encourage our readers to invest carefully and read the investor information provided by the Securities and Exchange Commission ("SEC") and/or the National Association of Securities Dealers ("NASD"). We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at: http://www.sec.gov/consumer/cyberfr.htm